These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25675301)

  • 1. Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition.
    Nowak-Sliwinska P; Weiss A; van Beijnum JR; Wong TJ; Kilarski WW; Szewczyk G; Verheul HM; Sarna T; van den Bergh H; Griffioen AW
    Cell Death Dis; 2015 Feb; 6(2):e1641. PubMed ID: 25675301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
    Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
    Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice.
    Bauerschlag DO; Schem C; Tiwari S; Egberts JH; Weigel MT; Kalthoff H; Jonat W; Maass N; Meinhold-Heerlein I
    Anticancer Res; 2010 Sep; 30(9):3355-60. PubMed ID: 20944108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
    Gotink KJ; Broxterman HJ; Labots M; de Haas RR; Dekker H; Honeywell RJ; Rudek MA; Beerepoot LV; Musters RJ; Jansen G; Griffioen AW; Assaraf YG; Pili R; Peters GJ; Verheul HM
    Clin Cancer Res; 2011 Dec; 17(23):7337-46. PubMed ID: 21980135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
    Wu CL; Ping SY; Yu CP; Yu DS
    Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
    Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
    J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
    Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
    Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.
    Chan ES; Patel AR; Hansel DE; Larchian WA; Heston WD
    Urology; 2012 Sep; 80(3):736.e1-5. PubMed ID: 22676953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of chronic stress on anti-angiogenesis of sunitinib in colorectal cancer models.
    Liu J; Deng GH; Zhang J; Wang Y; Xia XY; Luo XM; Deng YT; He SS; Mao YY; Peng XC; Wei YQ; Jiang Y
    Psychoneuroendocrinology; 2015 Feb; 52():130-42. PubMed ID: 25437118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
    Takeuchi A; Eto M; Shiota M; Tatsugami K; Yokomizo A; Kuroiwa K; Itsumi M; Naito S
    Int J Oncol; 2012 May; 40(5):1691-6. PubMed ID: 22344606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.